Comparison of Hemodynamic Changes With Morphine Versus Esmolol During Induction of Anaesthesia

October 1, 2023 updated by: Kenan Anwar Khan, Pakistan Navy Station Shifa Hospital

Comparison of Hemodynamic Changes With Morphine Versus Esmolol as an Adjuvant Agent During Induction of Anaesthesia

Comparing hemodynamic changes with morphine versus esmolol as an adjuvant agent during induction of Anaesthesia

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Comparing hemodynamic profile of patients during induction of General Anesthesia with intravenous morphine as an adjuvant drug versus Intravenous esmolol as an adjuvant agent,My aim is to study which drug has superior hemodynamic profile in terms of hemodynamic stability of patient requiring General Anesthesia.

Study Type

Interventional

Enrollment (Actual)

110

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Pakistan
    • Sind
      • Karachi, Sind, Pakistan, 46000
        • PNS Shifa Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • ASA 2 patients presenting for elective surgery.

Exclusion Criteria:

  • Patients having major cardiac disease.
  • Metastatic disease.
  • Pregnant females.
  • Those unwilling to be part of study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Morphine group
Half of participants will be comprising of morphine group
Drug: Intravenous morphine

Morphine group(an opioid), participants were given intravenous morphine(an opioid) at induction of General Anaesthesia before laryngoscopy and intubation.

The other group,Esmolol group(cardioselective beta blocker), participants were given intravenous esmolol(cardioselective beta blocker) during induction of General Anesthesia before laryngoscopy and intubation.

Other Names:
  • Intravenous esmolol
Experimental: Esmolol group
Half of participants will be comprising of esmolol group
Drug: Intravenous morphine

Morphine group(an opioid), participants were given intravenous morphine(an opioid) at induction of General Anaesthesia before laryngoscopy and intubation.

The other group,Esmolol group(cardioselective beta blocker), participants were given intravenous esmolol(cardioselective beta blocker) during induction of General Anesthesia before laryngoscopy and intubation.

Other Names:
  • Intravenous esmolol

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blood pressure
Time Frame: 06 months
Change in blood pressure between baseline value and post Intubation value will be measured in millimeter of mercury (mmHg).
06 months
Pulse rate
Time Frame: 06 months
Change in pulse rate between baseline value and post intubation value will be measured per minute.
06 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Pakistan Navy Station Shifa Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 28, 2022

Primary Completion (Actual)

June 15, 2023

Study Completion (Actual)

July 15, 2023

Study Registration Dates

First Submitted

August 29, 2023

First Submitted That Met QC Criteria

October 1, 2023

First Posted (Actual)

October 4, 2023

Study Record Updates

Last Update Posted (Actual)

October 4, 2023

Last Update Submitted That Met QC Criteria

October 1, 2023

Last Verified

October 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 433/8/22

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe